Significant Molecular Medicine Publications of 2019

Dr. Dave Hoon has published more than 375 peer-reviewed and co-authored articles.
See articles at pubmed.ncbi.nim.nih.gov.

Current status of gastrointestinal tract cancer brain metastasis and the use of blood-based cancer biomarker biopsy.
Assessment of Cell-Free microRNA by NGS Whole-Transcriptome Analysis in Cutaneous Melanoma Patients’ Blood.
Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma.
Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients.
The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells – a case of inter-tumor heterogeneity.
Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform.
A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients.
Inter-Tumor Heterogeneity-Melanomas Respond Differently to GM-CSF-Mediated Activation.
Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis.
Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis.
Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-?B1 Target SerpinE1 in Aggressive Glioblastoma Tumors.
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer.
STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth.
Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
Trends in Off-Label Drug Use in Ambulatory Settings: 2006-2015.
The Immune Landscape of Cancer.
Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer.
Regeneration Enhances Metastasis: A Novel Role for Neurovascular Signaling in Promoting Melanoma Brain Metastasis.
B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma.
Aneurysmal bone cyst treated with percutaneous doxycycline: is a single treatment sufficient?
UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors.
Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients.
Epigenetic profiling for the molecular classification of metastatic brain tumors.
Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features.
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-ß Superfamily.
Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
Comprehensive Characterization of Cancer Driver Genes and Mutations.
The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing’s Disease and Endocrine-Inactive Subtypes.
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
The metastatic microenvironment: Melanoma-microglia cross-talk promotes the malignant phenotype of melanoma cells.
Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.
KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Alternative splicing and cancer metastasis: prognostic and therapeutic applications.
miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.
Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease.
The Immune Landscape of Cancer.
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Pathogenic Germline Variants in 10,389 Adult Cancers.
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.
Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ; Cancer Genome Atlas Research Network, Cherniack AD, Beroukhim R, Meyerson M.
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.
Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.
Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.
Distinct histone modifications denote early stress-induced drug tolerance in cancer.
Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.
ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis.
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.
P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.
Hypomethylation of CNTFRa is associated with proliferation and poor prognosis in lower grade gliomas.
NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1a and p27Kip1 expression in malignant melanoma and other human tumors.
Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.
The RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas.
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
CCR4 is a determinant of melanoma brain metastasis.
Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-?B Pathway in Melanoma.
ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.
The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma.
LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015, 4, 1890-1907.
Liquid Biopsies for Assessing Metastatic Melanoma Progression.
Donald L. Morton, MD…. A Legendary Surgical Oncologist and Consummate Investigator.
Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?
B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
Rapid Oligo-Galacturonide Induced Changes in Protein Phosphorylation in Arabidopsis.
Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.
Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
In Situ Sodium Bisulfite Modification of Genomic DNA from Microdissected Melanoma Paraffin-Embedded Archival Tissues.
Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives.
Regiodivergent Enantioselective ?-Additions of Oxazolones to 2,3-Butadienoates Catalyzed by Phosphines: Synthesis of a,a-Disubstituted a-Amino Acids and N,O-Acetal Derivatives.
Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays.
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.
RASSF8 regulates progression of cutaneous melanoma through nuclear factor-?b.
Highly enantioselective construction of tertiary thioethers and alcohols via phosphine-catalyzed asymmetric ?-addition reactions of 5H-thiazol-4-ones and 5H-oxazol-4-ones: scope and mechanistic understandings.
Genomic Classification of Cutaneous Melanoma.
Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications.
The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching.
Enantioselective synthesis of 3-fluoro-3-allyl-oxindoles via phosphine-catalyzed asymmetric ?-addition of 3-fluoro-oxindoles to 2,3-butadienoates.
Lentivirus-induced ‘Smart’ dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma.
Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer.
A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
Transcriptional repression of IFNß1 by ATF2 confers melanoma resistance to therapy.
Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
Multi-platform Genome-wide Analysis of Melanoma Progression to Brain Metastasis.
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles.
Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome.
RASAL2 activates RAC1 to promote triple-negative breast cancer progression.
CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation.
Chromatin status of apoptosis genes correlates with sensitivity to chemo-, immune- and radiation therapy in colorectal cancer cell lines.
Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.
Donald Lee Morton: in memoriam (1934-2014).
Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome.
DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence.
The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis.
DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.
Molecular analysis of sentinel lymph nodes and search for molecular signatures of the metastatic potential of breast cancer.
BAG3 protein expression in melanoma metastatic lymph nodes correlates with patients’ survival.
Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis.
Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients.
Tumor necrosis factor-a and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin A.
Tanaka R, Donovan NC, Yu Q, Irie RF, Hoon DSB.
Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer.
Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.
Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma.
Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis.
B cells promote tumor progression via STAT3 regulated-angiogenesis.
Direct serum assay for microRNA in cancer patients.
Assessment of DNA methylation status in early stages of breast cancer development.
B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
Heterogeneous epigenetic regulation of TIMP3 in prostate cancer.
Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.
DNA methylation index and methylation profile of invasive ductal breast tumors.
Progression of cutaneous melanoma: implications for treatment.
Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread.
A landscape of driver mutations in melanoma.
Epigenetics of regional lymph node metastasis in solid tumors.
Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites.
Epigenetics of estrogen receptor-negative primary breast cancer.
Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation.
Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study.
The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells.
AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome.
Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma.
Epigenetic biomarkers in skin cancer.
Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.
The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis.
Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment.
Cell-free nucleic acids as biomarkers in cancer patients.
Prognostic molecular biomarkers for cutaneous malignant melanoma.
LINE-1 hypomethylation during primary colon cancer progression.
Molecular mechanisms of metastasis.
Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer.
A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes.
Kinesin 18A expression: clinical relevance to colorectal cancer progression.
Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients.
B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis.
Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma.
Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer.
Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma.
Identification of a quantitative MINT locus methylation profile predicting local regional recurrence of rectal cancer.
FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
Chemokine-chemokine receptor axes in melanoma brain metastasis.
High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma.
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment.
Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma.
Functional RET G691S polymorphism in cutaneous malignant melanoma.
Analysis of loss of heterozygosity in circulating DNA.
Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma.
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.
CpG island methylator phenotype predicts progression of malignant melanoma.
LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis.
Multimarker circulating DNA assay for assessing blood of prostate cancer patients.
Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial.

Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors.
Analysis of methylated circulating DNA in cancer patients’ blood.
Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer.
Multidetector computed tomography pulmonary angiography: does arm position affect pulmonary artery enhancement?
False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology.
Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes.
Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence.
Sequestosome 1 (SQSTM1) mutations in Paget’s disease of bone from the United States.
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.
The role of estrogen receptor in melanoma.
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer.
Effects of chemokines on tumor metastasis.
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial.
Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles.
Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis.
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21.
Hypermethylation of adenosine triphosphate-binding cassette transporter genes in primary hyperparathyroidism and its effect on sestamibi imaging.
Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis.
Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation.
Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients.
Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients.
Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.
Prediction of breast tumor progression by integrity of free circulating DNA in serum.
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis.
Estrogen receptor-alpha methylation predicts melanoma progression.
Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome.
Prospective multicenter trial of staging adequacy in colon cancer: preliminary results.
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
Molecular mechanisms of metastasis.
Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.
Methylation of p16 and Ras association domain family protein 1a during colorectal malignant transformation.
Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.
Molecular upstaging of sentinel lymph nodes in melanoma: where are we now?
A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy.
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.
The clinical significance of MAGEA3 expression in pancreatic cancer.
X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling.
Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma?
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Molecular diagnosis of micrometastasis in the sentinel lymph node.
Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
DNA vaccines for cancer treatment.
Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine.
Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer.
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.
Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.
Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells.
Synthesis of universal unmethylated control DNA by nested whole genome amplification with phi29 DNA polymerase.
Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis.
Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma.
Circulating nucleic acids in plasma and serum: past, present and future.
Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry.
Detection of mitochondrial DNA alterations in plasma of malignant melanoma patients.
Quantification of circulating DNA in the plasma and serum of cancer patients.
Circulating nucleic acids and proteomics of plasma/serum: clinical utility.
Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients.
Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes.
Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome.
Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma.
CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells.
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma.
Clinicopathological utility of molecular staging for melanoma patients undergoing sentinel lymphadenectomy.
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.
Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.
Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes.
Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients.
c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases.
Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer.
Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.
The use of molecular profiling of early colorectal cancer to predict micrometastases.
Assessment of genetic heterogeneity in tumors using laser capture microdissection.
Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Molecular lymphatic mapping of the sentinel lymph node.
Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis.
Overexpression of beta 1,4N-acetylgalactosaminyl- transferase mRNA as a molecular marker for various types of cancers.
Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.
Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
Detection of MAGE-A3 in breast cancer patients’ sentinel lymph nodes.
Microsatellite alterations detected in the serum of early stage breast cancer patients.
Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients.
Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients.
Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
Pathologic examination of sentinel lymph node for breast carcinoma.
Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy.
Molecular clonality of in-transit melanoma metastasis.
Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes.
Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial.
The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma.
Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients.
Microsatellite analysis of melanoma lesions using (CA)13 oligonucleotides as an internal probe.
Clinical significance of circulating DNA microsatellite markers in plasma of melanoma patients.
Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence.
PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas.
Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay.
Functional interleukin 4 receptor and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers: novel targets for immune therapy.
RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.
Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients.
Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer.
Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients.
Detection of carcinoembryonic antigen messenger RNA in lymph nodes from patients with colorectal cancer.
Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR.
Antibody responses to melanoma/melanocyte autoantigens in melanoma patients.
Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine.
Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients.
Cellular immuno-PCR. Detection of a carbohydrate tumor marker.
Detection of tyrosinase mRNA in melanoma by reverse transcription-PCR and electrochemiluminescence.
Human IgM antibodies to tumor-associated gangliosides share VHIII (V3-23) and VKIV family subgroups.
Assessment of messenger RNA of beta 1–>4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma.
Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?
Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine.
Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites.
707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.
Melanoma-associated antigens as messenger RNA detection markers for melanoma.
Current status of human melanoma vaccines: can they control malignant melanoma?
Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
Detection of metastatic breast cancer by beta-hCG polymerase chain reaction.
Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas.
Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma.
The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction.
Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay.
Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence.
Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients.
Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.
Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells.
Aberrant expression of gangliosides in human renal cell carcinomas.
Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells.
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.
Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens.
Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma.
A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.
Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response.
Growth inhibition and modulation of cell markers of melanoma by S-allyl cysteine.
Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4.
Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.
Ganglioside GM2 levels in human melanoma cells: inverse correlation with lysosomal beta-hexosaminidase A activity.
Cite Share
Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A.
Modulation of histamine type II receptors on CD8+ T cells by interleukin-2 and cimetidine.
Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.
Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.
Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.
Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity.
Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3.
Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.
Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells.
Immunosuppression by melanoma cells as a factor in the generation of metastatic disease.
Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells.
Modulation of human macrophage functions by gangliosides.
S-100 protein stimulates cellular proliferation.
Variations in lymphokine generation by individual lymph nodes draining human malignant tumors.
Active specific immunotherapy in malignant melanoma.
A comparison of solutions for lung preservation using pulmonary alveolar type II cell viability.
Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2.
Immunobiology of human cutaneous melanoma.
Isolation of lymphocytes from clotted blood.
Cyclophosphamide-induced alterations in human monocyte functions.
The regulatory effect of adherent cells on lymphokine activated killer cells.
Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells.
Reactivity of neoplastic cells of hairy cell leukemia with antisera to S-100 protein.
Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans.
Suppressor cell activity in melanoma-draining lymph nodes.
Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies.
A 6-thioguanine-resistant variant of the rat mammary adenocarcinoma 13762 that is more immunogenic.
Inhibition of lymphocyte motility by interleukin 2.
Analysis of mammary tumour cell metastasis and release of bound n-acetylneuraminic acid.
Chemoimmunotherapeutic effect of cyclophosphamide on the highly metastatic MAT 13762 tumor.
Increased metastatic ability and bone formation of a mammary adenocarcinoma in vivo after in vitro passaging.
Circulating immune complexes in rats bearing 6-thioguanine-resistant variants of the 13762 mammary adenocarcinoma.
Circulating immune complexes and immunoglobulin M-class rheumatoid factor in rats bearing mammary adenocarcinomas which vary in ability to metastasize.
A 6-thioguanine-resistant variant of the 13762 cell line which is no longer tumorigenic or metastatic.